• Fresenius completed the sale of 13,400,000 Fresenius Medical Care shares at €39 per share, raising approximately €524 million in gross proceeds.
• The sale reduced its stake to approximately 20% from approximately 25%.
• Since deconsolidation, the holding has fallen from approximately 32%, generating cumulative gross proceeds of approximately €2.3 billion.
• Net proceeds will be available for investment in growth platforms under the #FutureFresenius capital allocation priorities.
• Settlement is expected on November 16, 2026, with the remaining shares subject to a 90-day lock-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2433360_en) on November 12, 2026, and is solely responsible for the information contained therein.